Prescribing overview
A milk-protein-derived behavior supplement for dogs and cats. Reduced fear and greater willingness to explore may support more confident engagement; individual response varies.
Zylkene may support more confident engagement by helping some animals feel less fearful in challenging situations. In this reference, “confidence” describes observable comfort, exploration and willingness to participate; it is not presented as a separately validated personality change.
A small blinded crossover study of 20 dogs found fewer fearful postures and more olfactory exploration during veterinary examinations after alpha-casozepine. Physiologic measures did not differ. Those behavioral findings support the confidence interpretation within that setting, without proving broad effects in every animal.
Other results are mixed. A 2024 canine trial found a weak stress-reducing effect after short-term administration. A 2020 feline study found limited significant benefits, while an earlier placebo-controlled feline study reported improvements in several anxiety measures over 56 days. Treatment duration, patient population and measured outcomes matter.
Key prescribing checks
- Use alongside a tailored behavior plan. The practical goal is an animal better able to cope and engage, rather than simply appearing motionless.
- Here, confidence means less fearful avoidance and more comfortable exploration. It is an interpretation of behavior changes, not a proven universal personality effect or guaranteed outcome.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
Manufacturer-marketed supplement; not an FDA-approved animal-drug indicationSupport during stressful changes and challenging situations
Original canine studies concern defined anxiety-related outcomes. Supplement support should accompany assessment and behavior management.
Use / indication source ↗Cats
Manufacturer-marketed supplement; not an FDA-approved animal-drug indicationSupport for adaptation during stressful situations
Feline studies do not show identical results across settings; establish a patient-specific goal and follow-up.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Alpha-casozepine is a peptide-containing bovine casein hydrolysate. An anxiolytic-like GABA-related action is proposed in the research literature, but its clinical mechanism and magnitude of benefit are not fully established.
Absorption, distribution, metabolism and elimination
No established species-specific duration-of-action or systemic pharmacokinetic rule was verified in this reference. Manufacturer administration timing and study schedules should not be treated as interchangeable pharmacokinetic measurements.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Supplement safety information may be limited. A missing contraindication list does not establish safety in every species, during pregnancy, or with other treatments.
Zylkene
Original US-marketed alpha-casozepine supplement for dogs and cats; excludes Zylkene Plus.
Contraindications · when not to use
A formal contraindication list is not established in the reviewed source for this scope. This does not establish safety; confirm the exact product and full labeling.
Precautions & monitoring
- Review bovine-milk-derived ingredients and the full panel for the individual patient. A lactose-free claim does not establish suitability for every food-sensitivity history.
- A comprehensive reproductive-safety and contraindication assessment was not established in this review.
No comprehensive formal contraindication list was established from the reviewed manufacturer material. Limited published safety information must not be interpreted as universal clearance.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
The manufacturer markets the product as non-sedating. That claim does not establish an exhaustive adverse-event profile or eliminate the need to assess an unexpected response.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
No approved veterinary drug-dose regimen is established here for this supplement. Manufacturer serving directions are not equivalent to an evidence-based treatment protocol.
Manufacturer supplement directions use a daily, species- and weight-specific capsule amount; verify the package strength with the veterinarian. These directions are not an approved animal-drug regimen or an automatic weight-based prescription.
For an anticipated event, the manufacturer suggests beginning beforehand; some animals need an earlier start. Plan timing with the veterinarian rather than expecting an immediate rescue effect.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
Zylkene
Original US-marketed alpha-casozepine supplement for dogs and cats; excludes Zylkene Plus.
- Manufacturer statements about use with medications are not pair-by-pair veterinary interaction validation; the full treatment plan needs review.
Monitoring
Record avoidance, fearful posture, exploration and ability to participate in the behavior plan. Assess whether changes improve welfare in the situations that matter for the patient; a response in one setting may not generalize to others.
Client counseling
Capsules may be given whole or opened, following current manufacturer directions. Check the formula if the animal has a food-sensitivity history.
The manufacturer states it can be given with medications, but this is not a complete interaction assessment for every drug or supplement combination. Disclose the full treatment list and do not change prescribed behavior medication independently.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Keep the actual package and follow its storage, expiry and handling instructions. Confirm that replacement products are original Zylkene rather than Zylkene Plus or another calming blend.
Brands, formulations & ingredient identity
Active ingredients
Alpha-casozepine
Other searchable names: Zylkene · Zylkène · Alpha casozepine · Alpha-casozepine · Alpha-s1 casozepin · Alpha-S1 tryptic casein · Hydrolyzed bovine milk protein
Original Zylkene contains alpha-casozepine derived from bovine milk protein. Zylkene Plus also contains white fish muscle hydrolysate and is a separate combination, not an automatic equivalent.
The manufacturer describes the original product as lactose-free. Its milk-derived identity still matters when reviewing food sensitivities and the complete ingredient panel.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Zylkene
- Formulation
- Original alpha-casozepine oral capsules
- Label / product scope
- Dogs · Cats
Choose the appropriate strength and current species/weight directions; excludes Zylkene Plus.
Product label / source ↗References & review status
Clinical reference updated October 28, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
